FDA
-
-
-
-
-
-
-
Verastem presents two-year follow-up data for ovarian cancer therapy
-
-
-
-
-
-
-
Verastem discontinues lung cancer trial to focus on KRAS G12D program
-
-
-
-
-
-
-
Verastem Oncology Announces Proposed Public Offering of Common Stock
-
-
-
-
-
-
-
Verastem partner reports 68.8% response rate for lung cancer drug in China study
-
-
-
-
-
-
-
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
-
-
-
-
-
-
-
Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Announces U.S. IND Clearance of VS-7375
-
322,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

